scholarly journals Point-of-Care RNA-Based Diagnostic Device for COVID-19

Diagnostics ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 165 ◽  
Author(s):  
Ting Yang ◽  
Yung-Chih Wang ◽  
Ching-Fen Shen ◽  
Chao-Min Cheng

At the end of 2019, the novel coronavirus disease (COVID-19), a fast-spreading respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported in Wuhan, China and has now affected over 123 countries globally [...]

2021 ◽  
Vol 11 (1) ◽  
pp. 01-18
Author(s):  
Shweta Jain ◽  
◽  
Pankaj Kumar Jain ◽  
Ramakant Yadav ◽  
Surendra Kumar Jain ◽  
...  

The sudden outbreak of 2019 novel coronavirus (2019-nCoV) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated from Wuhan, China. SARS-CoV-2 causes severe respiratory illness and becomes a major threat for humanity. Recently the entire scientist, researchers and physicians all over the countries focused to find the treatment of this pandemic disease. Numerous drugs and or vaccines have been trialed for prevention and treatment against 2019-nCoV but no therapy has been shown effective to date. Currently, numerous vaccines are under clinical investigation and mRNA-1273 vaccine (LNP- encapsulated mRNA vaccine encoding S protein) from Moderna is ahead. Although chloroquine, hydroxychloroquine, remdesivir and many other drugs had recommended against SARS-CoV-2, but still they are not the guarantee treatment of COVID-19. Recently, India, America, Russia and China introduced vaccines against COVID-19 in the market, however assurance of their 100% effectiveness are doubtful. The speed of daily new cases threatens the world and urges the scientist to crack this pandemic condition. KEYWORDS: 2019-nCoV; Chloroquine; COVID-19; Moderna; Respiratory disease; Remdesivir.


2020 ◽  
Vol 222 ◽  
pp. 259-261 ◽  
Author(s):  
Elisabetta Venturini ◽  
Giordano Palmas ◽  
Carlotta Montagnani ◽  
Elena Chiappini ◽  
Francesco Citera ◽  
...  

2020 ◽  
Vol 12 (2) ◽  
pp. 156-157
Author(s):  
Mohammad Mostafa Ansari Ramandi ◽  
Mohammadreza Baay ◽  
Nasim Naderi

The disaster due to the novel coronavirus disease 2019 (COVID-19) around the world has made investigators enthusiastic about working on different aspects of COVID-19. However, although the pandemic of COVID-19 has not yet ended, it seems that COVID-19 compared to the other coronavirus infections (the Middle East Respiratory Syndrome [MERS] and Severe Acute Respiratory Syndrome [SARS]) is more likely to target the heart. Comparing the previous presentations of the coronavirus family and the recent cardiovascular manifestations of COVID-19 can also help in predicting possible future challenges and taking measures to tackle these issues.


2021 ◽  
Vol 58 (2) ◽  
pp. 613-620
Author(s):  
Mustafa Amdani, Dr. Swaroopa Chakole

BACKGROUND The expanse of the coronavirus disease 2019 or COVID-19 is huge. The impact is multispectral and affected almost all aspects of human life. SUMMARY Respiratory impact of the COVID-19 is the most felt and widely reported impact. As the novel coronavirus maintained its history of affecting lungs as seen previously in severe acute respiratory syndrome (SARS) outbreak. Ventilators and oxygen support system are required mostly in comorbid patients particularly amongpatientsbearing illnesses like asthma, bronchial impairment and so on. CONCLUSION More study needs to be done in order to assess the impact on the respiratory functioning of the body. Respiratory care must be including proper instruments so that more efficient result can be obtained. Research is needed to promote the invention of specific therapy for targeted action for respiratory functioning improvement.


The Analyst ◽  
2021 ◽  
Author(s):  
Linlin Zhuang ◽  
Jiansen Gong ◽  
Ming Ma ◽  
Yongxin Ji ◽  
Peilong Tian ◽  
...  

The novel coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been surging rapidly around the world, which exposes humanity to unprecedented economic, social and...


Viruses ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 582 ◽  
Author(s):  
Nadin Younes ◽  
Duaa W. Al-Sadeq ◽  
Hadeel AL-Jighefee ◽  
Salma Younes ◽  
Ola Al-Jamal ◽  
...  

The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.


2020 ◽  
Vol 21 (9) ◽  
pp. 3275 ◽  
Author(s):  
Manoocher Soleimani

Coronaviruses (CoVs), including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and the novel coronavirus disease-2 (SARS-CoV-2) are a group of enveloped RNA viruses that cause a severe respiratory infection which is associated with a high mortality [...]


The Lancet ◽  
2004 ◽  
Vol 363 (9403) ◽  
pp. 99-104 ◽  
Author(s):  
Y Guan ◽  
JSM Peiris ◽  
B Zheng ◽  
LLM Poon ◽  
KH Chan ◽  
...  

Diagnostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 449
Author(s):  
Tivani P. Mashamba-Thompson ◽  
Paul K. Drain

Point-of-care (POC) diagnostic services are commonly associated with pathology laboratory services. This issue presents a holistic approach to POC diagnostics services from a variety of disciplines including pathology, radiological and information technology as well as mobile technology and artificial intelligence. This highlights the need for transdisciplinary collaboration to ensure the efficient development and implementation of point-of-care diagnostics. The advent of the novel coronavirus 2019 (COVID-19) pandemic has prompted rapid advances in the development of new POC diagnostics. Global private and public sector agencies have significantly increased their investment in the development of POC diagnostics. There is no longer a question about the availability and accessibility of POC diagnostics. The question is “how can POC diagnostic services be integrated into health services in way that is useful and acceptable in the COVID-19 era?”.


Sign in / Sign up

Export Citation Format

Share Document